WO1999007738A3 - Human orphan receptor ntr-1 - Google Patents

Human orphan receptor ntr-1 Download PDF

Info

Publication number
WO1999007738A3
WO1999007738A3 PCT/US1998/016202 US9816202W WO9907738A3 WO 1999007738 A3 WO1999007738 A3 WO 1999007738A3 US 9816202 W US9816202 W US 9816202W WO 9907738 A3 WO9907738 A3 WO 9907738A3
Authority
WO
WIPO (PCT)
Prior art keywords
ntr
orphan receptor
provides
human
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/016202
Other languages
French (fr)
Other versions
WO1999007738A2 (en
Inventor
Piotr J Masiakowski
Jodi Morris
David M Valenzuela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Procter and Gamble Co
Original Assignee
Regeneron Pharmaceuticals Inc
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc, Procter and Gamble Co filed Critical Regeneron Pharmaceuticals Inc
Priority to CA002299619A priority Critical patent/CA2299619A1/en
Priority to JP2000506239A priority patent/JP2001512667A/en
Priority to EP98939199A priority patent/EP1019502A2/en
Priority to AU87676/98A priority patent/AU8767698A/en
Publication of WO1999007738A2 publication Critical patent/WO1999007738A2/en
Publication of WO1999007738A3 publication Critical patent/WO1999007738A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention provides for a nucleic acid sequence, designated as HUMAN NTR-1, that encodes a novel orphan receptor expressed in pancreas and fetal heart. The invention also provides assay systems that may be used to detect and/or measure ligands that bind the HUMAN NTR-1 gene product. The present invention also provides for diagnostic and therapeutic methods based on the interaction between NTR-1 and agents that initiate signal transduction through binding to NTR-1.
PCT/US1998/016202 1997-08-06 1998-08-04 Human orphan receptor ntr-1 Ceased WO1999007738A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002299619A CA2299619A1 (en) 1997-08-06 1998-08-04 Human orphan receptor ntr-1
JP2000506239A JP2001512667A (en) 1997-08-06 1998-08-04 Human orphan receptor NTR-1
EP98939199A EP1019502A2 (en) 1997-08-06 1998-08-04 Human orphan receptor ntr-1
AU87676/98A AU8767698A (en) 1997-08-06 1998-08-04 Novel orphan receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5486997P 1997-08-06 1997-08-06
US60/054,869 1997-08-06

Publications (2)

Publication Number Publication Date
WO1999007738A2 WO1999007738A2 (en) 1999-02-18
WO1999007738A3 true WO1999007738A3 (en) 1999-04-15

Family

ID=21994032

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/016202 Ceased WO1999007738A2 (en) 1997-08-06 1998-08-04 Human orphan receptor ntr-1

Country Status (5)

Country Link
EP (1) EP1019502A2 (en)
JP (1) JP2001512667A (en)
AU (1) AU8767698A (en)
CA (1) CA2299619A1 (en)
WO (1) WO1999007738A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2277925A1 (en) 1997-01-14 1998-07-16 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6.alpha. and 6.beta.
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
JP4303883B2 (en) 1997-09-18 2009-07-29 ジェネンテック・インコーポレーテッド TNFR homologue of DcR3 polypeptide
WO1999026977A1 (en) * 1997-11-24 1999-06-03 Biogen, Inc. Novel receptors opg-2
EP1037908A2 (en) * 1997-12-16 2000-09-27 Incyte Pharmaceuticals, Inc. Human tumor necrosis factor-r2-like proteins
DE19809978A1 (en) * 1998-03-09 1999-09-16 Basf Ag New soluble member of tumor necrosis factor receptor family, useful for identification specific modulators and for treating disease e.g. tumors
AU3369199A (en) * 1998-03-30 1999-10-18 Eli Lilly And Company Therapeutic applications of mature flint (mflint) polypeptides or opg3, a memberof the tnf receptor superfamily
WO2001060397A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
WO2000037094A2 (en) * 1998-12-22 2000-06-29 Eli Lilly And Company Therapeutic applications of flint polypeptides
WO2000047772A2 (en) 1999-02-10 2000-08-17 Genset Polymorphic markers of the lsr gene
JP2003512020A (en) * 1999-03-04 2003-04-02 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Tumor necrosis factor receptor 6α and tumor necrosis factor receptor 6β
US6329159B1 (en) * 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
US6965012B1 (en) * 1999-03-30 2005-11-15 Eli Lilly And Company Flint polypeptide analogs
US6627199B1 (en) 1999-07-09 2003-09-30 Amgen Inc Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
WO2001010908A1 (en) * 1999-08-04 2001-02-15 Amgen Inc. Ntr3, a member of the tnf-receptor supergene family
AU783682B2 (en) 1999-08-04 2005-11-24 Amgen, Inc. Fhm, a novel member of the TNF ligand supergene family
US7338787B2 (en) 2000-01-14 2008-03-04 Serono Genetics Institute S.A. Nucleic acids encoding OBG3 globular head and uses thereof
JP2003531588A (en) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド Multivalent antibodies and their uses
DE60136816D1 (en) 2000-07-27 2009-01-15 Genentech Inc SEQUENTIAL ADMINISTRATION OF CPT-11 AND APO-2L POLYPEPTIDE
EP1409544B1 (en) 2001-07-03 2009-06-17 Genentech, Inc. Human dr4 antibodies and uses thereof
ES2618543T3 (en) 2005-11-23 2017-06-21 Genentech, Inc. Methods and compositions related to B lymphocyte assays

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447851A (en) * 1992-04-02 1995-09-05 Board Of Regents, The University Of Texas System DNA encoding a chimeric polypeptide comprising the extracellular domain of TNF receptor fused to IgG, vectors, and host cells
DE19654610A1 (en) * 1995-12-22 1997-06-26 Amgen Inc Osteoproteger
WO1998030694A2 (en) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
EP0861850A1 (en) * 1997-02-04 1998-09-02 Smithkline Beecham Corporation Tumor necrosis related receptor, TR4

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447851A (en) * 1992-04-02 1995-09-05 Board Of Regents, The University Of Texas System DNA encoding a chimeric polypeptide comprising the extracellular domain of TNF receptor fused to IgG, vectors, and host cells
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
DE19654610A1 (en) * 1995-12-22 1997-06-26 Amgen Inc Osteoproteger
WO1998030694A2 (en) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
EP0861850A1 (en) * 1997-02-04 1998-09-02 Smithkline Beecham Corporation Tumor necrosis related receptor, TR4

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HILLIER L ET AL: "Human cDNA clone 366305", EMBL SEQUENCE DATABASE, 16 August 1996 (1996-08-16), HEIDELBERG DE, XP002091562 *
HILLIER L ET AL: "Human cDNA clone 592256", EMBL SEQUENCE DATABASE, 18 January 1997 (1997-01-18), HEIDELBERG DE, XP002091560 *

Also Published As

Publication number Publication date
WO1999007738A2 (en) 1999-02-18
AU8767698A (en) 1999-03-01
CA2299619A1 (en) 1999-02-18
EP1019502A2 (en) 2000-07-19
JP2001512667A (en) 2001-08-28

Similar Documents

Publication Publication Date Title
WO1999007738A3 (en) Human orphan receptor ntr-1
WO1999060119A3 (en) Multivalent t cell receptor complexes
WO1998050547A3 (en) Human toll-like receptor proteins, related reagents and methods
WO1999033982A3 (en) Human genes and gene expression products i
WO1999038972A8 (en) Human genes and gene expression products ii
NO891818L (en) T4 RECEPTOR PROTEIN, RELATED DNA SEQUENCES AND PREPARATION thereof.
NO934235L (en) Use of nucleic acid analogues for diagnostic and analytical procedures
CA2176463A1 (en) Hu-b1.219, a novel human hematopoietin receptor
WO1999058559A3 (en) Factors affecting tumor necrosis factor receptor releasing enzyme activity
WO2002020762A8 (en) Tnf receptor-like molecules and uses thereof
WO2001066753A3 (en) Human genes and gene expression products
WO2002014500A3 (en) Human genes and gene expression products
WO2001068705A3 (en) Il-17 receptor like molecules and uses thereof
WO2001068859A3 (en) Il-17 receptor like molecules and uses thereof
WO2001073034A3 (en) Beta-like glycoprotein hormone polypeptide and heterodimer
CA2294476A1 (en) Semaphorin receptors
MX9606584A (en) Mass-sensitive biosensors.
EP1136547A3 (en) Adamts polypeptides, nucleic acids encoding them, and uses thereof
WO1999033967A3 (en) Novel nucleic acid and polypeptide with homology to the tnf-receptors
MXPA03004578A (en) Novel polypeptides involved in immune response.
WO1996039511A3 (en) A c5a-like seven transmembrane receptor
CA2273855A1 (en) Novel feline fc epsilon receptor alpha chain nucleic acid molecules, proteins and uses thereof
WO2001074903A3 (en) Cd20/ige-receptor like molecules and uses thereof
DE69434498D1 (en) DREAMING MUSCLE KINASE (DMK), A TYROSINE KINASE SUPERFAMILY RECEPTOR
WO2000050455A3 (en) Antigen to systemic lupus erythematosis and diagnostic assay

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 502588

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 87676/98

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2299619

Country of ref document: CA

Ref country code: CA

Ref document number: 2299619

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998939199

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09485313

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998939199

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998939199

Country of ref document: EP